iBio (IBIO) vs Rein Therapeutics (RNTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
iBio (IBIO) has outperformed Rein Therapeutics (RNTX) over the past year, gaining 5.7% versus a loss of 44.7%. Over five years, RNTX leads with a -96.2% price change compared with -99.8% for IBIO. Rein Therapeutics is the larger company by market cap ($66.4 million vs $59.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IBIO | RNTX |
|---|---|---|
| Share price | $0.92 | $0.7693 |
| Market cap | $59.16M | $66.37M |
| 1-day change | -8.91% | -2.46% |
| YTD return | -52.33% | -33.68% |
| 1-year return | +5.75% | -44.65% |
| 5-year return | -99.80% | -96.19% |
| EPS (TTM) | $-0.32 | $-1.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.82 | $2.18 |
| 52-week low | $0.78 | $0.694 |
| Distance from 52-week high | -75.92% | -64.71% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +518.48% | +679.93% |
| Average volume | 727.93K | 430.81K |
| Shares outstanding | 64.31M | 86.27M |
| Employees | 23 | 10 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBIO has outperformed RNTX by 50.4 percentage points over the past year.
About iBio
IBIO stock →iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies.
Healthcare · Biotechnology · 23 employees
About Rein Therapeutics
RNTX stock →Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Healthcare · Biotechnology · 10 employees
IBIO vs RNTX FAQ
Which is bigger, iBio or Rein Therapeutics?
Rein Therapeutics (RNTX) is larger, with a market capitalization of $66.37M compared with $59.16M for iBio (IBIO).
Which stock has performed better over the past year, IBIO or RNTX?
IBIO returned +5.75% over the past 12 months, compared with -44.65% for RNTX (price return, excluding dividends). Past performance does not predict future results.
Are iBio and Rein Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.